SUMOylation of SAMHD1 at Lysine 595 is required for HIV-1 restriction in non-cycling cells.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
28 07 2021
Historique:
received: 16 05 2020
accepted: 05 07 2021
entrez: 29 7 2021
pubmed: 30 7 2021
medline: 5 8 2021
Statut: epublish

Résumé

SAMHD1 is a cellular triphosphohydrolase (dNTPase) proposed to inhibit HIV-1 reverse transcription in non-cycling immune cells by limiting the supply of the dNTP substrates. Yet, phosphorylation of T592 downregulates SAMHD1 antiviral activity, but not its dNTPase function, implying that additional mechanisms contribute to viral restriction. Here, we show that SAMHD1 is SUMOylated on residue K595, a modification that relies on the presence of a proximal SUMO-interacting motif (SIM). Loss of K595 SUMOylation suppresses the restriction activity of SAMHD1, even in the context of the constitutively active phospho-ablative T592A mutant but has no impact on dNTP depletion. Conversely, the artificial fusion of SUMO2 to a non-SUMOylatable inactive SAMHD1 variant restores its antiviral function, a phenotype that is reversed by the phosphomimetic T

Identifiants

pubmed: 34321470
doi: 10.1038/s41467-021-24802-5
pii: 10.1038/s41467-021-24802-5
pmc: PMC8319325
doi:

Substances chimiques

SAM Domain and HD Domain-Containing Protein 1 EC 3.1.5.-
SAMHD1 protein, human EC 3.1.5.-
Lysine K3Z4F929H6

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4582

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI150455
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI136581
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM086262
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150451
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© 2021. The Author(s).

Références

Baldauf, H.-M. et al. SAMHD1 restricts HIV-1 infection in resting CD4+ T cells. Nat. Med. 18, 1682–1689 (2012).
pubmed: 22972397 doi: 10.1038/nm.2964
Descours, B. et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T-cells. Retrovirology 9, 87 (2012).
pubmed: 23092122 pmcid: 3494655 doi: 10.1186/1742-4690-9-87
Hrecka, K. et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474, 658–661 (2011).
pubmed: 21720370 pmcid: 3179858 doi: 10.1038/nature10195
Laguette, N. et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474, 654–657 (2011).
pubmed: 21613998 pmcid: 3595993 doi: 10.1038/nature10117
Berger, A. et al. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection. PLoS Pathog. 7, 1–12 (2011).
doi: 10.1371/journal.ppat.1002425
Goldstone, D. C. et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480, 379–382 (2011).
pubmed: 22056990 doi: 10.1038/nature10623
Powell, R. D., Holland, P. J., Hollis, T. & Perrino, F. W. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J. Biol. Chem. 286, 43596–43600 (2011).
pubmed: 22069334 pmcid: 3243528 doi: 10.1074/jbc.C111.317628
Lahouassa, H. et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 13, 223–228 (2012).
pubmed: 22327569 pmcid: 3771401 doi: 10.1038/ni.2236
Diamond, T. L. et al. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 279, 51545–51553 (2004).
pubmed: 15452123 doi: 10.1074/jbc.M408573200
Amie, S. M., Noble, E. & Kim, B. Intracellular nucleotide levels and the control of retroviral infections. Virology 436, 247–254 (2013).
pubmed: 23260109 doi: 10.1016/j.virol.2012.11.010
Lim, E. S. et al. The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe 11, 194–204 (2012).
pubmed: 22284954 pmcid: 3288607 doi: 10.1016/j.chom.2012.01.004
Goujon, C. et al. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 4, 2 (2007).
pubmed: 17212817 pmcid: 1779362 doi: 10.1186/1742-4690-4-2
Kim, B., Nguyen, L. A., Daddacha, W. & Hollenbaugh, J. A. Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 Proviral DNA synthesis kinetics in human primary monocyte-derived macrophages. J. Biol. Chem. 287, 21570–21574 (2012).
pubmed: 22589553 pmcid: 3381122 doi: 10.1074/jbc.C112.374843
Schmidt, S. et al. SAMHD1’s protein expression profile in humans. J. Leukoc. Biol. 98, 5–14 (2015).
pubmed: 25646359 doi: 10.1189/jlb.4HI0714-338RR
Franzolin, E. et al. The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. Proc. Natl Acad. Sci. USA 110, 14272–14277 (2013).
pubmed: 23858451 pmcid: 3761606 doi: 10.1073/pnas.1312033110
Cribier, A., Descours, B., Valadão, A., Laguette, N. & Benkirane, M. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep. 3, 1036–1043 (2013).
pubmed: 23602554 doi: 10.1016/j.celrep.2013.03.017
Welbourn, S., Dutta, S. M., Semmes, O. J. & Strebel, K. Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1. J. Virol. 87, 11516–11524 (2013).
pubmed: 23966382 pmcid: 3807338 doi: 10.1128/JVI.01642-13
White, T. E. et al. The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe 13, 441–451 (2013).
pubmed: 23601106 doi: 10.1016/j.chom.2013.03.005
Schott, K. et al. Dephosphorylation of the HIV-1 restriction factor SAMHD1 is mediated by PP2A-B55α holoenzymes during mitotic exit. Nat. Commun. 9, 2227 (2018).
pubmed: 29884836 pmcid: 5993806 doi: 10.1038/s41467-018-04671-1
Tramentozzi, E. et al. The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592. Cell Cycle. 17, 1102–1114 (2018).
pubmed: 30039733 pmcid: 6110608 doi: 10.1080/15384101.2018.1480216
Coquel, F. et al. SAMHD1 acts at stalled replication forks to prevent interferon induction. Nature 557, 57–61 (2018).
pubmed: 29670289 doi: 10.1038/s41586-018-0050-1
Yan, J. et al. CyclinA2-cyclin-dependent kinase regulates SAMHD1 protein phosphohydrolase domain. J. Biol. Chem. 290, 13279–13292 (2015).
pubmed: 25847232 pmcid: 4505580 doi: 10.1074/jbc.M115.646588
Arnold, L. H. et al. Phospho-dependent regulation of SAMHD1 oligomerisation couples catalysis and restriction. PLoS Pathog. 11, 1–30 (2015).
doi: 10.1371/journal.ppat.1005194
Welbourn, S. & Strebel, K. Low dNTP levels are necessary but may not be sufficient for lentiviral restriction by SAMHD1. Virology 488, 271–277 (2016).
pubmed: 26655245 doi: 10.1016/j.virol.2015.11.022
Bhattacharya, A. et al. Effects of T592 phosphomimetic mutations on tetramer stability and dNTPase activity of SAMHD1 can not explain the retroviral restriction defect. Sci. Rep. 6, 31353 (2016).
pubmed: 27511536 pmcid: 4980677 doi: 10.1038/srep31353
Antonucci, J. M. et al. SAMHD1-mediated HIV-1 restriction in cells does not involve ribonuclease activity. Nat. Med. 22, 1072–1074 (2016).
pubmed: 27711056 pmcid: 5069697 doi: 10.1038/nm.4163
Ryoo, J., Hwang, S.-Y., Choi, J., Oh, C. & Ahn, K. SAMHD1, the Aicardi-Goutières syndrome gene and retroviral restriction factor, is a phosphorolytic ribonuclease rather than a hydrolytic ribonuclease. Biochem. Biophys. Res. Commun. 477, 1–5 (2016).
doi: 10.1016/j.bbrc.2016.07.013
Ryoo, J. et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat. Med. 20, 936–941 (2014).
pubmed: 25038827 pmcid: 4318684 doi: 10.1038/nm.3626
Seamon, K. J., Sun, Z., Shlyakhtenko, L. S., Lyubchenko, Y. L. & Stivers, J. T. SAMHD1 is a single-stranded nucleic acid binding protein with no active site-associated nuclease activity. Nucleic Acids Res. 43, 6486–6499 (2015).
pubmed: 26101257 pmcid: 4513882 doi: 10.1093/nar/gkv633
Seamon, K. J., Bumpus, N. N. & Stivers, J. T. Single-stranded nucleic acids bind to the tetramer interface of SAMHD1 and prevent formation of the catalytic homotetramer. Biochemistry 55, 6087–6099 (2016).
pubmed: 27775344 doi: 10.1021/acs.biochem.6b00986
Hendriks, I. A. & Vertegaal, A. C. O. A comprehensive compilation of SUMO proteomics. Nat. Rev. Mol. Cell Biol. 11, 1630–1649 (2016).
Hendriks, I. A. et al. Site-specific characterization of endogenous SUMOylation across species and organs. Nat. Commun. 9, 1–17 (2018).
doi: 10.1038/s41467-018-04957-4
Everett, R. D., Boutell, C. & Hale, B. G. Interplay between viruses and host sumoylation pathways. Nat. Rev. Microbiol. 11, 400–411 (2013).
pubmed: 23624814 doi: 10.1038/nrmicro3015
Pichler, A., Fatouros, C., Lee, H. & Eisenhardt, N. SUMO conjugation – a mechanistic view. Biomol. Concepts 8, 13–36 (2017).
pubmed: 28284030 doi: 10.1515/bmc-2016-0030
Lapenta, V. et al. SMT3A, a human homologue of the S. cerevisiae SMT3 gene, maps to chromosome 21qter and defines a novel gene family. Genomics 40, 362–366 (1997).
pubmed: 9119407 doi: 10.1006/geno.1996.4556
Sampson, D. A., Wang, M. & Matunis, M. J. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276, 21664–21669 (2001).
pubmed: 11259410 doi: 10.1074/jbc.M100006200
Rodriguez, M. S., Dargemont, C. & Hay, R. T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276, 12654–12659 (2001).
pubmed: 11124955 doi: 10.1074/jbc.M009476200
Kerscher, O. SUMO junction-what’s your function? New insights through SUMO-interacting motifs. EMBO Rep. 8, 550–555 (2007).
pubmed: 17545995 pmcid: 2002525 doi: 10.1038/sj.embor.7400980
Bailey, D. & O’Hare, P. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling. Biochem. J. 392, 271–281 (2005).
pubmed: 16117725 pmcid: 1316262 doi: 10.1042/BJ20050873
Ristic, M., Brockly, F., Piechaczyk, M. & Bossis, G. Detection of protein–protein interactions and posttranslational modifications using the proximity ligation assay: application to the study of the SUMO pathway. Methods Mol. Biol. 1449, 279–290 (2016).
pubmed: 27613043 doi: 10.1007/978-1-4939-3756-1_17
Bagchi, S., Fredriksson, R. & Wallén-Mackenzie, Å. In situ proximity ligation assay (PLA). Methods Mol. Biol. 1318, 149–159 (2015).
pubmed: 26160573 doi: 10.1007/978-1-4939-2742-5_15
Fukuda, I. et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol. 16, 133–140 (2009).
pubmed: 19246003 doi: 10.1016/j.chembiol.2009.01.009
Songyang, Z. et al. Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr. Biol. 4, 973–982 (1994).
pubmed: 7874496 doi: 10.1016/S0960-9822(00)00221-9
Saitoh, H. & Hinchey, J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275, 6252–6258 (2000).
pubmed: 10692421 doi: 10.1074/jbc.275.9.6252
Su, H.-L. & Li, S. S.-L. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 296, 65–73 (2002).
pubmed: 12383504 doi: 10.1016/S0378-1119(02)00843-0
Beauclair, G. et al. JASSA: a comprehensive tool for prediction of SUMOylation sites and SIMs. Bioinformatics 31, 3483–3491 (2015).
pubmed: 26142185 doi: 10.1093/bioinformatics/btv403
Hendriks, I. A. et al. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat. Struct. Mol. Biol. 24, 325–336 (2017).
pubmed: 28112733 doi: 10.1038/nsmb.3366
St Gelais, C. et al. Identification of cellular proteins interacting with the retroviral restriction factor SAMHD1. J. Virol. 88, 5834–5844 (2014).
doi: 10.1128/JVI.00155-14
Yan, J. et al. Tetramerization of SAMHD1 is required for biological activity and inhibition of HIV infection. J. Biol. Chem. 288, 10406–10417 (2013).
pubmed: 23426366 pmcid: 3624423 doi: 10.1074/jbc.M112.443796
Soria-Bretones, I. et al. DNA end resection requires constitutive sumoylation of CtIP by CBX4. Nat. Commun. 8, 113 (2017).
Meng, F., Qian, J., Yue, H., Li, X. & Xue, K. SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase. Cell Cycle 15, 1724–1732 (2016).
pubmed: 27163259 pmcid: 4957593 doi: 10.1080/15384101.2016.1182267
Chu, Y. & Yang, X. SUMO E3 ligase activity of TRIM proteins. Oncogene 30, 1108–1116 (2011).
pubmed: 20972456 doi: 10.1038/onc.2010.462
Li, Z. et al. TRIM 21-mediated proteasomal degradation of SAMHD 1 regulates its antiviral activity. EMBO Rep. 21, 1–18 (2020).
doi: 10.15252/embr.201847528
Ribet, D. & Cossart, P. Ubiquitin, SUMO, and NEDD8: key targets of bacterial pathogens. Trends Cell Biol. 28, 926–940 (2018).
pubmed: 30107971 pmcid: 7028394 doi: 10.1016/j.tcb.2018.07.005
Wang, Z. et al. Functionality of redox-active cysteines is required for restriction of retroviral replication by SAMHD1. Cell Rep. 24, 815–823 (2018).
pubmed: 30044979 pmcid: 6067006 doi: 10.1016/j.celrep.2018.06.090
Johnson, E. S. Protein modification by SUMO. Annu. Rev. Biochem. 73, 355–382 (2004).
pubmed: 15189146 doi: 10.1146/annurev.biochem.73.011303.074118
Parker, J. L. et al. SUMO modification of PCNA is controlled by DNA. EMBO J. 27, 2422–2431 (2008).
pubmed: 18701921 pmcid: 2518684 doi: 10.1038/emboj.2008.162
Zilio, N. et al. DNA-dependent SUMO modification of PARP-1. DNA Repair (Amst.). 12, 761–773 (2013).
pubmed: 23871147 pmcid: 3744807 doi: 10.1016/j.dnarep.2013.07.001
Jentsch, S. & Psakhye, I. Control of nuclear activities by substrate-selective and protein-group SUMOylation. Annu. Rev. Genet. 47, 167–186 (2013).
pubmed: 24016193 doi: 10.1146/annurev-genet-111212-133453
He, J. et al. HIV-1 infection of microglia. Nature 385, 645–649 (1997).
pubmed: 9024664 doi: 10.1038/385645a0
Manel, N. et al. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467, 214–217 (2010).
pubmed: 20829794 pmcid: 3051279 doi: 10.1038/nature09337
Freed, E. O. & Martin, M. A. HIV-1 infection of non-dividing cells. Nature 369, 107 (1994).
pubmed: 8192816 doi: 10.1038/369107b0
Zamborlini, A. et al. Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect. J. Biol. Chem. 286, 21013–21022 (2011).
pubmed: 21454548 pmcid: 3121452 doi: 10.1074/jbc.M110.189274
Dafinca, R. et al. C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal dementia. Stem Cells 34, 2063–2078 (2016).
pubmed: 27097283 pmcid: 4979662 doi: 10.1002/stem.2388
van Wilgenburg, B., Browne, C., Vowles, J. & Cowley, S. A. Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. PLoS ONE 8, e71098 (2013).
Karlsson, K. R. et al. Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp. Hematol. 36, 1167–1175 (2008).
pubmed: 18550257 pmcid: 2635571 doi: 10.1016/j.exphem.2008.04.009

Auteurs

Charlotte Martinat (C)

INSERM U944, CNRS UMR 7212, Genomes & Cell Biology of Disease Unit, Institut de Recherche Saint-Louis, Université de Paris, Hôpital Saint-Louis, Paris, France.

Arthur Cormier (A)

INSERM U944, CNRS UMR 7212, Genomes & Cell Biology of Disease Unit, Institut de Recherche Saint-Louis, Université de Paris, Hôpital Saint-Louis, Paris, France.

Joëlle Tobaly-Tapiero (J)

INSERM U944, CNRS UMR 7212, Genomes & Cell Biology of Disease Unit, Institut de Recherche Saint-Louis, Université de Paris, Hôpital Saint-Louis, Paris, France.

Noé Palmic (N)

INSERM U944, CNRS UMR 7212, Genomes & Cell Biology of Disease Unit, Institut de Recherche Saint-Louis, Université de Paris, Hôpital Saint-Louis, Paris, France.

Nicoletta Casartelli (N)

Institut Pasteur, Virus and Immunity Unit, CNRS-UMR3569, Paris, France.
Vaccine Research Institute, Créteil, France.

Bijan Mahboubi (B)

Emory School of Medicine, Atlanta, USA.

Si'Ana A Coggins (SA)

Emory School of Medicine, Atlanta, USA.

Julian Buchrieser (J)

Institut Pasteur, Virus and Immunity Unit, CNRS-UMR3569, Paris, France.
Vaccine Research Institute, Créteil, France.
James Martin Stem Cell Facility, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Mirjana Persaud (M)

Albert Einstein College of Medicine, Microbiology and Immunology, Bronx, NY, USA.

Felipe Diaz-Griffero (F)

Albert Einstein College of Medicine, Microbiology and Immunology, Bronx, NY, USA.

Lucile Espert (L)

IRIM, University of Montpellier, UMR 9004 CNRS, Montpellier, France.

Guillaume Bossis (G)

IGMM, Univ Montpellier, CNRS, Montpellier, France.

Pascale Lesage (P)

INSERM U944, CNRS UMR 7212, Genomes & Cell Biology of Disease Unit, Institut de Recherche Saint-Louis, Université de Paris, Hôpital Saint-Louis, Paris, France.

Olivier Schwartz (O)

Institut Pasteur, Virus and Immunity Unit, CNRS-UMR3569, Paris, France.
Vaccine Research Institute, Créteil, France.

Baek Kim (B)

Emory School of Medicine, Atlanta, USA.

Florence Margottin-Goguet (F)

Université de Paris, Institut Cochin, INSERM, CNRS, PARIS, France.

Ali Saïb (A)

INSERM U944, CNRS UMR 7212, Genomes & Cell Biology of Disease Unit, Institut de Recherche Saint-Louis, Université de Paris, Hôpital Saint-Louis, Paris, France.

Alessia Zamborlini (A)

INSERM U944, CNRS UMR 7212, Genomes & Cell Biology of Disease Unit, Institut de Recherche Saint-Louis, Université de Paris, Hôpital Saint-Louis, Paris, France. alessia.zamborlini@universite-paris-saclay.fr.
Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ. Paris-Sud, Université Paris-Saclay, Gif-sur-Yvette, France. alessia.zamborlini@universite-paris-saclay.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH